Ultragenyx Pharmaceutical Inc. (RARE)

164,813 Shares in Ultragenyx Pharmaceutical Inc. $RARE Bought by Deutsche Bank AG

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

Ultragenyx Nabs FDA Nod for First Gene Therapy

Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of Gene Therapy for Glycogen Storage Disease Type 1a Transcript

Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx: Undervalued Ahead Of Two FDA Decisions

Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up Following Strong Earnings

Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call Transcript

Ultragenyx Pharmaceutical Q2 Earnings Call Highlights

Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline

Entropy Technologies LP Grows Position in Ultragenyx Pharmaceutical Inc. $RARE

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)